.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The PRODIGE 24 trial compared adjuvant modified FOLFIRINOX with gemcitabine in patients who had undergone resection for pancreatic ductal adenocarcinoma and had recovered sufficiently for postoperative chemotherapy. The trial established a major improvement in disease-free survival with FOLFIRINOX and also demonstrated a meaningful overall-survival advantage during longer follow-up. The findings helped shift postoperative pancreatic-cancer care toward more intensive combination chemotherapy for fit patients rather than gemcitabine alone. Clinically, the value of the study extends beyond the drug comparison. It reinforces the principle that surgery is only one component of treatment for pancreatic cancer, with systemic therapy playing an essential role in controlling recurrence risk. At the same time, FOLFIRINOX has substantial toxicity, so patient fitness, postoperative recovery, performance status and access to experienced oncology support influence whether the regimen is appropriate. For surgeons, the trial supports early multidisciplinary planning so that referral, resection and postoperative systemic treatment are coordinated from the outset.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The PRODIGE 24 trial compared adjuvant modified FOLFIRINOX with gemcitabine in patients who had undergone resection for pancreatic ductal adenocarcinoma and had recovered sufficiently for postoperative chemotherapy. The trial established a major improvement in disease-free survival with FOLFIRINOX and also demonstrated a meaningful overall-survival advantage during longer follow-up. The findings helped shift postoperative pancreatic-cancer care toward more intensive combination chemotherapy for fit patients rather than gemcitabine alone. Clinically, the value of the study extends beyond the drug comparison. It reinforces the principle that surgery is only one component of treatment for pancreatic cancer, with systemic therapy playing an essential role in controlling recurrence risk. At the same time, FOLFIRINOX has substantial toxicity, so patient fitness, postoperative recovery, performance status and access to experienced oncology support influence whether the regimen is appropriate. For surgeons, the trial supports early multidisciplinary planning so that referral, resection and postoperative systemic treatment are coordinated from the outset.
4 weeks back
Discover how catalytic nanozymes redefine autoimmune disease therapy by establishing a physiological redox set-point to restore immune tolerance without broad immunosuppression.
Last week
Recent research reveals that downregulating YAP1/TAZ-TEAD via Hippo signaling triggers spontaneous human trophoblast syncytialization in 3D cultures, illuminating placental biology and preeclampsia.
3 weeks back
A landmark comparative study evaluates atrial electrophysiology across humans, swine, and rodents. By linking cellular recordings with transcriptomics and in silico modeling, researchers resolve cross-species gaps, explaining translational failures to advance targeted therapies for atrial arrhythmias.
3 weeks back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
last month
Researchers have developed an innovative ultrasound-responsive nano-contrast agent that co-delivers CIITA-siRNA and rapamycin directly to inflamed thyroid tissue, significantly reducing autoimmune injury and thyroid autoantibodies in preclinical models of Hashimoto thyroiditis.
3 weeks back
